AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$DVA

What DaVita (DVA) Said on Its Q3 Earnings Call

DaVita (DVA) reported Q3 earnings, highlighting a 20% year-over-year increase in technology spending and a national rollout of expanded hemodialysis dialyzers. The company expects technology investment growth to decelerate but not decline in 2027. DaVita raised its outlook for Integrated Kidney Care, projecting at least $65 million in adjusted operating income for 2026.

Original reporting
finance.yahoo.com
Published Oct 30, 2026, 10:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 10:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What DaVita (DVA) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$DVABearishHigh
01

Why it matters

The earnings release narrows guidance, suggesting slower near‑term growth, but highlights operational improvements and a buyback that could support the stock.

02

Market read

DaVita's earnings and guidance affect healthcare investors and may influence peer valuations in the dialysis sector.

03

What to watch

Long‑term benefits from expanded dialyzer rollout and mortality improvements may boost future earnings.

Relevance 9/10Novelty 9/10Timing: post-earnings today

Background

DaVita's Q3 earnings call covered cost trends, a technology spend increase, rollout of expanded hemodialysis dialyzers, higher IKC outlook, narrowed full‑year adjusted operating income guidance, share repurchases, and policy impacts on reimbursement.

Company-level read

Ticker impact

$DVABearishHigh confidence
Context

DaVita reported Q3 results, narrowed full-year adjusted operating income guidance to $2.175‑$2.25 B and disclosed share repurchases of ~1.1 M shares.

Expected impact

likely modest pressure as guidance narrows, partially offset by buyback support

Evidence & confidence

Guidance narrowing suggests slower growth, but the buyback and improved IKC outlook may provide upside support.

Market effects

Sector

Dialysis and broader healthcare sector may face similar earnings pressure, though IKC growth could benefit peers.

Regional

US healthcare equities could be modestly affected.

Global

Limited to US healthcare investors.

Counterpoint

What could challenge this read

Buyback and technology investments could drive upside despite narrowed guidance.

Key entities

  • company
    DaVita Inc.

    US dialysis services provider reporting Q3 results.

  • company
    Humana

    Partner in chronic kidney disease program.

Read at source← All news

StoryDaVita reports Q3 2026 earnings beat, raises full‑year EPS guidance and notes China impairment

Also covered by

6 outlets

Related articles

$DVAMed

Washington state accuses largest dialysis providers DaVita, Fresenius of suppressing competition

Washington state sued DaVita and Fresenius Medical Care, alleging they suppress competition by requiring nephrologists to sign noncompete agreements, reducing patient treatment options. The state seeks to void these agreements and impose fines. DaVita denies wrongdoing; Fresenius did not comment. The FTC is also investigating. DaVita operates 51 centers in Washington, Fresenius 29, with some areas having only one provider.

finance.yahoo.com
$DVAMedAI 8/10

DaVita (DVA) Q3 2026 Earnings Call Transcript

DaVita (DVA) reported Q3 2026 adjusted operating income of $561M and EPS of $3.82. The company highlighted clinical advancements in fluid management and expanded HD dialyzers, expecting a national rollout by November. DaVita raised its Integrated Kidney Care (IKC) guidance to $65M for 2026, citing improved savings rates and partnerships. Full-year 2026 adjusted operating income is projected to be $2.175B-$2.25B, with EPS between $14.30-$15.20.

finance.yahoo.com
$DVAHighAI 8/10

DaVita Inc (DVA) (Q3 2026) Earnings Call Highlights: IKC Guidance Raised, Expanded HD

DaVita Inc (DVA) narrowed its 2026 adjusted operating income and EPS guidance due to higher US dialysis costs. Revenue per treatment grew 1.1% YoY, while patient care costs rose 2.4%. The new ESRD rule's 3.5% rate increase is expected to have a net impact of 1.5% to 2% for 2027. CEO Javier Rodriguez highlighted growth plans for the IKC business and the company's stance on the HHS Kidney Care National Plan.

finance.yahoo.com
$DVAHighAI 9/10

DaVita’s (NYSE:DVA) Q3 2026: beats on revenue but stock drops

DaVita (DVA) reported Q3 2026 revenue of $3.58B, beating estimates by 1.7% YoY. Adjusted EPS of $3.82 exceeded expectations by 6.9%. Management raised full-year EPS guidance to $14.75. Operating margin remained steady at 14%, but free cash flow margin declined to 7.7% from 19.7% YoY. Sales volumes increased 1.2% YoY, reversing a prior decline.

finance.yahoo.com
$DVAMedAI 8/10

DaVita shares tumble as earnings outlook disappoints

DaVita Inc (DVA) reported Q3 earnings of $3.82 per share, beating estimates, with revenue up 12.8% YoY. However, shares fell 9.5% after hours as full-year guidance of $14.30-$15.20 EPS missed expectations. The company cited modest U.S. dialysis growth and higher patient care costs. DVA also recorded a $62M impairment charge related to its China business and maintained its full-year free cash flow guidance.

investing.com